Preparation method of SHP2 inhibitor ARRY-558
The synthesis of SHP2 inhibitor ARRY-558 through specific reactions with 3-bromo-1,2,4-triazine and (R)-N-((S)-1,3-dihydrospiro[indene-2,4'-piperidinyl]-1-yl)-2-methylpropane-2-sulfenamide addresses the limitations of existing inhibitors by improving selectivity and membrane permeability, making it effective for cancer and autoimmune disease treatment.
Patent Information
- Application Number
- CN202311482361.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-11-08
- Publication Date
- 2024-12-06
AI Technical Summary
Existing SHP2 inhibitors face challenges such as lack of selectivity and poor membrane permeability due to targeting the highly conserved catalytic sites, making them ineffective in treating cancer and autoimmune diseases.
Development of two synthesis routes for SHP2 inhibitor ARRY-558 involving specific reactions with 3-bromo-1,2,4-triazine and (R)-N-((S)-1,3-dihydrospiro[indene-2,4'-piperidinyl]-1-yl)-2-methylpropane-2-sulfenamide to produce ARRY-558 through halogenation and subsequent reactions with 2-amino-3-chloropyridine-4-thiol sodium salt, followed by removal of protecting groups.
The synthesis methods yield ARRY-558 with improved selectivity and membrane permeability, enhancing its potential as a potent SHP2 inhibitor for cancer and autoimmune disease treatment.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention belongs to the field of chemical drug synthesis and relates to two preparation methods of SHP2 inhibitor ARRY-558. Background Art
[0002] SHP2, also known as PTPN11, is a phosphatase that can dephosphorylate substrate proteins. It is a key signaling node and regulatory factor, an important molecule that regulates cell function, and is involved in and regulates almost all biological processes. SHP2 is a convergence node of multiple signaling pathways including Ras-Raf-MEK-ERK, JAK-STAT, PI3K-AKT-mTOR, and PD-1 / PD-L1 pathways. Its overactivation is inseparable from the occurrence of cancer and autoimmune diseases. In the past few decades, it has been considered an "undruggable" target. This is because SHP2 inhibitors can be divided into two categories according to their sites of action: inhibitors that act on catalytic sites and inhibitors that act on allosteric sites. The early development of SHP2 inhibitors mainly focused on the study of catalytic sites. The catalytic domain of phosphatases is highly conserved, and catalytic site inhibitors generally lack selectivity. At the same time, SHP2 inhibitors targeting the catalytic site have disadvantages such as being overly conservative and having poor membrane permeability. After several years, it was still difficult to overcome this difficulty. Until 2016, Novartis announced the first allosteric inhibitor SHP099 for SHP2 in "Natrue", shifting the research focus to the allosteric mode of SHP2.
[0003] At present, 15 SHP2 inhibitors have entered the clinical trial stage, among which RMC-4630, JAB-3068, JAB-3312, BBP-398, TNO-155, etc. have entered Phase 2 clinical trials and are used in combination with multiple drugs to improve the effect of tumor treatment. Among them, JAB-3068 and TNO-155 are first-generation inhibitors, and JAB-3312 is a second-generation inhibitor, and the activity of the second generation is 20 times stronger than that of the first generation. From the current clinical dosage, the second-generation molecule JAB-3312 is one twentieth of the first generation. In addition to the above-mentioned drugs, there are other SHP2 inhibitors in preclinical or clinical research, such as Pfizer's ARRY-558 (PF-07284892), which has entered Phase I clinical trials and achieved good results. The best combination therapy and the most appropriate drug dosage are being gradually explored. Summary of the invention
[0004] In view of the above situation, the preparation of SHP2 inhibitor ARRY-558 is very important. The present inventors have invented two preparation schemes of SHP2 inhibitor ARRY-558 through experimental research.
[0005] The compounds of the present invention are prepared by the following two routes:
[0006] Solution 1
[0007]
[0008] 1) reacting the raw material 3-bromo-1,2,4-triazine with (R)-N-((S)-1,3-dihydrospiro[indene-2,4'-piperidinyl]-1-yl)-2-methylpropane-2-sulfenamide to obtain (R)-N-((S)-1'-(1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidinyl]-1-yl)-2-methylpropane-2-sulfenamide;
[0009] 2) halogenating to obtain the compound (R)-N-((S)-1'-(6-halogeno-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidinyl]-1-yl)-2-methylpropane-2-sulfenamide;
[0010] 3) The compound obtained in step 2) is reacted with 2-amino-3-chloropyridine-4-thiol sodium salt to obtain compound (R)-N-((S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-yl)-2-methylpropane-2-sulfenamide
[0011] 4) Finally, the tert-butylsulfonyl protecting group is removed to obtain the target compound ARRY-558.
[0012] Solution 2
[0013]
[0014] 1) reacting a raw material 3-halogenated-1,2,4-triazine with (S)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine to obtain (S)-1'-(1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine;
[0015] 2) further halogenating to obtain compound (S)-(6-halogeno-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine;
[0016] 3) The compound obtained in step 2) is subjected to amino protection with di-tert-butyl dicarbonate to obtain (R)-N-((S)-1'-(6-halo-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-yl)-2-methylpropane-2-amide;
[0017] 4) reacting with 2-amino-3-chloropyridine-4-thiol sodium salt to obtain compound (R)-N-((S)-1'-(6-((2-amino-3-chloropyridin-4-yl)sulfur)-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-yl)-2-methylpropane-2-amide;
[0018] 5) Finally, the amino protecting group is removed to obtain the target compound ARRY-558. Specific embodiments
[0019] The present invention is further described below by way of examples, but the contents of the present invention are not limited thereby.
[0020] Example 1
[0021]
[0022] Step A
[0023] Compound (R)-N-((S)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-yl)-2-methylpropane-2-sulfinamide (163 mg, 0.53 mmol) was diluted with dioxane (2 mL) and DIEA (326 pL, 1.9 mmol) was added. After stirring for 5 minutes, 3-bromo-1,2,4-triazine (85 mg, 0.53 mmol) was added and the reaction was heated to 50 °C and stirred for 3 hours. After the reaction was cooled, it was diluted with DCM / IPA and 10% sodium carbonate. The layers were separated and the aqueous solution was extracted twice with DCM / IPA. The organics were combined, dried over MgSO4, filtered and concentrated. The residue was purified by column chromatography to give compound (R)-N-((S)-1'-(1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-yl)-2-methylpropane-2-sulfenamide (31 mg, yield 15%). LC-MS (ESI): m / z=385.5 [M+H] + .
[0024] Step B
[0025] Add (R)-N-((S)-1'-(1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-yl)-2-methylpropane-2-sulfinamide (30 g, 77.1 mmol), THF (300 mL), TMEDA (19.7 g, 169.6 mmol) to the reaction flask, replace the reaction system with nitrogen three times, cool to -78 ° C, add n-butyl lithium (2.5 M in THF, 68 mL), slowly heat to -10 ° C, stir for 2 h and then cool to -78 ° C, add iodine (23.5 g, 92.5 mmol) THF solution (100 mL) to the reaction system, and stir at -78 ° C for 2 h. Heat to 0 ° C, quench the reaction with saturated sodium sulfite solution, separate the liquid, and extract the aqueous phase with ethyl acetate twice. Combine the organic phases and dry them over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by column chromatography to obtain compound (R)-N-((S)-1'-(6-iodo-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-yl)-2-methylpropane-2-sulfenamide (15 g, yield 38%). LC-MS (ESI): m / z=511.4 [M+H] + .
[0026] Step C
[0027] (R)-N-((S)-1'-(6-iodo-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-yl)-2-methylpropane-2-sulfinamide (66 mg, 0.13 mmol) and sodium 2-amino-3-chloropyridine-4-thiolate (48 mg, 0.26 mmol) were diluted and dissolved with NMP (437 pL, 0.13 mmol), and then DIEA (46 pL, 0.26 mmol) was added and heated to 110°C under argon. After stirring for 12 hours, the reaction was cooled, diluted with ethyl acetate, and washed with water and brine. The ethyl acetate layer was dried over MgSO4, filtered and concentrated. The residue was purified by column chromatography to give compound (R)-N-((S)-1'-(6-((2-amino-3-chloropyridin-4-yl)sulfanyl)-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-yl)-2-methylpropane-2-sulfenamide (50 mg, yield 70%). LC-MS (ESI): m / z=544.1 [M+H] + .
[0028] Step D
[0029] (R)-N-((S)-1'-(6-((2-amino-3-chloropyridin-4-yl)sulfanyl)-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-yl)-2-methylpropane-2-sulfenamide (20 mg, 0.037 mmol) was diluted with dioxane (1 mL), and then HCl (0.37 mmol) was added. After stirring for 30 minutes, the reaction was diluted with DCM and saturated aqueous sodium bicarbonate solution. After stirring the mixture for 10 minutes, the layers were separated, the dichloromethane was dried over MgSO4, filtered and concentrated. The residue was purified by column chromatography to finally give the target compound ARRY-558 (14.7 mg, yield 90%). LC-MS (ESI): m / z=439.9[M+H] + . 1 HNMR(400MHz, CDCl3)δ:8.2(s,1H),7.76(d,1H),7.2-7.35(m,4H),6.15(d,1H),4.92(br, 2H),4.78(br,1H),4.01(s,1H),3.37(m,2H),3.14(d,1H),2.78(d,1H),1.3-1.91(m,7H).
[0030] Example 2
[0031]
[0032] Step A
[0033] Compound (S)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine (107 mg, 0.53 mmol) was diluted with dioxane (2 mL), and DIEA (326 pL, 1.9 mmol) was added. After stirring for 5 minutes, 3-chloro-1,2,4-triazine (61 mg, 0.53 mmol) was added, and the reaction was heated to 50 ° C and stirred for 3 hours. After the reaction was cooled, it was diluted with DCM / IPA and 10% sodium carbonate. The layers were separated and the aqueous solution was extracted twice with DCM / IPA. The organics were combined, dried over MgS04, filtered and concentrated. The residue was purified by column chromatography to give compound (S)-1'-(1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine (22 mg, yield 15%). LC-MS (ESI): m / z=281.4[M+H]+.
[0034] Step B
[0035] Add (S)-1'-(1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine (22g, 77.1mmol), THF (300mL), TMEDA (19.7g, 169.6mmol) to the reaction bottle, replace the reaction system with nitrogen three times, cool to -78°C, add n-butyl lithium (2.5M in THF, 68mL), slowly heat to -10°C, stir for 2h and then cool to -78°C, add iodine (23.5g, 92.5mmol) THF solution (100mL) to the reaction system, and stir at -78°C for 2h. Heat to 0°C, quench the reaction with saturated sodium sulfite solution, separate the liquids, and extract the aqueous phase with ethyl acetate twice. Combine the organic phases and dry them over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by column chromatography to obtain compound (S)-(6-halo-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine (12.4 g, yield 40%). LC-MS (ESI): m / z = 407.3 [M+H] + .
[0036] Step C
[0037] (S)-(6-halogeno-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine (41 g, 0.1 mol) and triethylamine (20 g, 0.2 mol), 250 ml of dichloromethane, and di-tert-butyl dicarbonate (26 g, 0.12 mol) were added to a three-necked flask, gradually heated to room temperature and stirred at this temperature for reaction, and the reaction was monitored by TLC. After the reaction was completed, the solvent was evaporated under reduced pressure, and dichloromethane (200 ml×2) was added to the residue for extraction, and the obtained organic phase was dried over anhydrous magnesium sulfate, filtered, and concentrated to obtain compound (R)-N-((S)-1'-(6-halogeno-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-yl)-2-methylpropane-2-amide (48.5 g, yield 95%). LC-MS (ESI): m / z = 507.4 [M+H] + .
[0038] Step D
[0039] (R)-N-((S)-1'-(6-halo-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-yl)-2-methylpropane-2-amide (66 mg, 0.13 mmol) and sodium 2-amino-3-chloropyridine-4-thiolate (48 mg, 0.26 mmol) were diluted and dissolved with NMP (437 pL, 0.13 mmol), and then DIEA (46 pL, 0.26 mmol) was added and heated to 110°C under argon. After stirring for 12 hours, the reaction was cooled, diluted with ethyl acetate, and washed with water and brine. The ethyl acetate layer was dried over MgSO4, filtered and concentrated. The residue was purified by column chromatography to give compound (R)-N-((S)-1'-(6-((2-amino-3-chloropyridin-4-yl)sulfanyl)-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-yl)-2-methylpropane-2-amide (49 mg, yield 70%). LC-MS (ESI): m / z=540.1 [M+H] + .
[0040] Step E
[0041] A dichloromethane solution (150 ml) of (R)-N-((S)-1'-(6-((2-amino-3-chloropyridin-4-yl)sulfur)-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-yl)-2-methylpropane-2-amide (54 g, 0.1 mol) was added to a three-necked flask, followed by the addition of trifluoroacetic acid (12.54 g, 0.11 mol). The resulting mixture was stirred at room temperature for 10 hours. After the reaction was completed, the mixture was quenched with sodium bicarbonate solution (100 ml), and then extracted with dichloromethane (150 ml×2). The resulting organic phase was washed with sodium bicarbonate, dried over anhydrous magnesium sulfate, and concentrated to obtain the target compound ARRY-558 (41 g, yield 94%). LC-MS (ESI): m / z=439.9[M+H] + . 1 H NMR(400MHz, CDCl3)δ:8.2(s,1H),7.76(d,1H),7.2-7.35(m,4H),6.15(d,1H),4.92(br, 2H),4.78(br,1H),4.01(s,1H),3.37(m,2H),3.14(d,1H),2.78(d,1H),1.3-1.91(m,7H).
[0042] The above examples are only used to illustrate the embodiments of the present invention, but the present invention is not limited to the above examples. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected, and the scope of the present invention to be protected is defined by the claims and their equivalents.
Claims
1. The first method for preparing the SHP2 inhibitor ARRY-558, characterized in that: The specific preparation steps are as follows: 1) reacting the raw material 3-bromo-1,2,4-triazine with (R)-N-((S)-1,3-dihydrospiro[indene-2,4'-piperidinyl]-1-yl)-2-methylpropane-2-sulfenamide to obtain (R)-N-((S)-1'-(1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidinyl]-1-yl)-2-methylpropane-2-sulfenamide; 2) halogenating to obtain the compound (R)-N-((S)-1'-(6-halogeno-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidinyl]-1-yl)-2-methylpropane-2-sulfenamide; 3) reacting the compound obtained in step 2) with 2-amino-3-chloropyridine-4-thiol sodium salt to obtain compound (R)-N-((S)-1'-(6-((2-amino-3-chloropyridin-4-yl)sulfur)-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-yl)-2-methylpropane-2-sulfenamide; 4) Finally, the tert-butylsulfonyl protecting group is removed to obtain the target compound ARRY-558.
2. The second method for preparing the SHP2 inhibitor ARRY-558 is characterized in that: The specific preparation steps are as follows: 1) The raw material 3-halogenated-1,2,4-triazine reacts with (S)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine to obtain (S)-1'-(1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidine]-1-amine 2) Then halogenate to obtain compound (S)-(6-halogenated-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine 3) The compound obtained in step 2) is amino protected with di-tert-butyl dicarbonate to obtain (R)-N-((S)-1'-(6-halo-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-yl)-2-methylpropane-2-amide 4) Then react with 2-amino-3-chloropyridine-4-thiol sodium salt to obtain compound (R)-N-((S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazine-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-yl)-2-methylpropane-2-amide 5) Finally, the amino protecting group is removed to obtain the target compound ARRY-558.
3. A method for preparing a SHP2 inhibitor ARRY-558 according to claim 1-2, characterized in that: In step (1) of Scheme 2, the halogen group of 3-halo-1,2,4-triazine can be Cl, Br, I, etc.; the amino protecting group in Scheme 2 can be selected from one of Cbz, Boc, Fmoc, and Bn, and Boc is selected in this scheme.
4. A method for preparing a SHP2 inhibitor ARRY-558 according to claim 1-2, characterized in that: In step (1) of scheme 1 and scheme 2, the reaction temperature is selected from 10-200°C, the reaction time is selected from 0-72h, and the solvent is selected from one or more of N,N-dimethylformamide (DMF), dichloromethane, etc. The alkaline agent is selected from one or more of sodium carbonate, potassium carbonate, triethylamine, sodium hydroxide, potassium hydroxide, sodium bicarbonate, sodium hydride, etc. Purification can be performed by washing the filter cake, filtering through a column, slurrying or recrystallization.
5. A method for preparing a SHP2 inhibitor ARRY-558 according to claim 1-2, characterized in that: In step (2) of scheme 1 and scheme 2, X in the halogenation reaction is a Br or I group. The halogenation reagent in the reaction is selected from one or more of NBS, Br2, PBr3, POBr3, CuBr, TBAB, dibromohydantoin, NIS, I2, and ICl. The reaction temperature is -90-30°C, the reaction time is 0-5h, and the reaction solvent is selected from one or more of ether solvents such as THF, DME, MTBE, ether, and butyl ether and hydrocarbon solvents such as n-hexane, n-heptane, n-pentane, petroleum ether, benzene, and toluene.
6. A method for preparing a SHP2 inhibitor ARRY-558 according to claim 1-2, characterized in that: In step (3) of scheme 1 and step (4) of scheme 2, the reaction temperature is selected from 20-150° C., the reaction time is selected from 10-24 h, the solvent is selected from one or more of NMP, ether, acetone, ethyl acetate, chloroform and benzene, and the purification can be selected from column, slurrying, Prep-TLC, Prep-HPLC or recrystallization.
7. A method for preparing a SHP2 inhibitor ARRY-558 according to claim 1-2, characterized in that: In step (3) of scheme 2, the reaction solvent is selected from one or more of an alcohol solvent, dichloromethane, acetone, 1,4-dioxane, ethyl acetate, tetrahydrofuran, and water; the temperature is room temperature; the molar ratio of the compound to di-tert-butyl dicarbonate is 1:1-1:3; the reaction is carried out under the action of an acid binding agent, and the acid binding agent is selected from one or more of potassium carbonate, sodium carbonate, triethylamine, and N-ethyldiisopropylamine.
8. A method for preparing the SHP2 inhibitor ARRY-558 according to claim 1-2, characterized in that: In step (4) of scheme 1, the reaction temperature is selected from 10-200° C., the reaction time is selected from 0-72 h, the solvent is selected from one or more of DCM, 1,2-dichloroethane, chlorobenzene, acetonitrile, THF, 2-MeTHF, DMF, DME, 1,4-dioxane, H2O, NMP, DMAC, and DMSO, the acid used is selected from one or two of trifluoroacetic acid and hydrochloric acid, and the acid equivalent is selected from ≥1 eq. The product is selected from the crude product and used downwardly, and the purification can be selected from column, slurrying, Prep-TLC, Prep-HPLC or recrystallization.
9. A method for preparing the SHP2 inhibitor ARRY-558 according to claim 1-2, characterized in that: In step (5) of scheme 2, the deamino protecting group reagent is trifluoroacetic acid (TFA) or hydrogen chloride gas, the reaction solvent is selected from one or more of DCM, 1,2-dichloroethane, chlorobenzene, acetonitrile, THF, 2-MeTHF, DMF, DME, 1,4-dioxane, H2O, NMP, DMAC, and DMSO, the molar ratio of the compound to the deamino protecting group reagent is 1:1-1:3; the reaction temperature is room temperature, and the purification can be selected from column, slurrying, Prep-TLC, Prep-HPLC, or recrystallization.
